12 $10 Stocks That Will Triple
In this article, we discuss 12 $10 stocks that will triple. If you want to skip our discussion on the latest stock market landscape, head over to 5 $10 Stocks That Will Triple. According to JPMorgan,...
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company's lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
6.85 | |
7.05 | |
- | |
7.18 | |
6.8 | |
2.63-11.67 | |
304 M | |
44 369 K | |
0 | |
-0.16 | |
1.836 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
In this article, we discuss 12 $10 stocks that will triple. If you want to skip our discussion on the latest stock market landscape, head over to 5 $10 Stocks That Will Triple. According to JPMorgan,...
By David Bautz, PhD NASDAQ:EPIX READ THE FULL EPIX RESEARCH REPORT Business Update Updated Phase1/2 Data for Masofaniten Presented at ASCO Genitourinary Cancers Symposium On January 25, 2024, ESS...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also: